Galectin-3 and its relationship with the state of coronary arteries in patients with acute myocardial infarction and concomitant obesity
DOI:
https://doi.org/10.14739/2310-1210.2019.1.155781Keywords:
ischemic heart disease, myocardial infarction, obesity, Galectin-3Abstract
The aim of the study - to evaluate the condition of the coronary arteries according to quartile of galectin-3 serum level in patients with acute myocardial infarction and obesity.
Materials and methods. A total of 31 patients with acute myocardial infarction and I and II degree of obesity were examined. A coronaroventriculography was performed with stenting of the infarct-dependent coronary artery within 12 hours from the pain syndrome onset. Galectin-3 was determined using a Human Galectin-3 ELISA kit (China). The degree of coronary atherosclerosis severity was assessed by coronaroventriculography (CVG) using the Gensini score.
Results. The most common atherosclerotic lesion was found in the right interventricular artery – 89 % of cases followed by the right coronary artery (59.3 %), about half of patients (48.1 %) had a lesion of the circumflex artery. The greatest vulnerability of the right interventricular artery was accompanied by the highest mean stenosis values – 77.3 % followed by the right coronary artery, the mean stenosis value of which was 68.2 %. The development of acute myocardial infarction predominantly (57.1 %) was due to occlusion of the right interventricular artery. The increase in the level of galectin-3 to 23.48–41.42 ng/ml, which corresponds to 3–4 quartiles of galectin-3 level, was associated with an increase in the number of affected vessels and segments with high Gensini scores.
Conclusions. The right interventricular and right coronary arteries are the most vulnerable according to the angiographic findings, both in terms of frequency and degree of lesion, and frequency of hemodynamically significant stenoses in patients with acute myocardial infarction and obesity. An increase in galectin-3 level up to 3 and 4 quartiles is accompanied by a parallel increase in parameters characterizing the progression of atherosclerotic lesion of the coronary arteries. Galectin-3 can be considered as a marker of atherosclerotic process in patients with acute myocardial infarction and obesity due to the association between galectin-3 level and the degree of coronary artery lesion severity.
References
Rao, M., Xavier, D., Devi, P., Sigamani, A., Faruqui, A., Gupta, R., et al. (2015). Prevalence, treatments and outcomes of coronary artery disease in Indians: A systematic review. Indian Heart J, 67(4), 302–310. doi: 10.1016/j.ihj.2015.05.003.
Fuchs, F. C., Ribeiro, J. P., Fuchs, F. D., Wainstein, M. V., Bergoli, L. C., Wainstein, R. V., et al. (2016). Syntax score and major adverse cardiac events in patients with suspected coronary artery disease: Results from a cohort study in a university-affiliated hospital in Southern Brazil. Arq Bras Cardiol, 107(3), 207–215. doi: 10.5935/abc.20160111.
Bekler, A., Altun, B., Gazi, E., Temiz, A., Barutçu, A., Güngör, Ö., et al. (2015). Comparison of the GRACE risk score and the TIMI risk index in predicting the extent and severity of coronary artery disease in patients with acute coronary syndrome. Anatol J Cardiol, 15(10), 801–806. doi: 10.5152/akd.2014.5802.
Komiyama, K., Nakamura, M., Tanabe, K., Niikura, H., Fujimoto, H., Oikawa, K., et al. (2018). In-hospital mortality analysis of Japanese patients with acute coronary syndrome using the Tokyo CCU Network database: Applicability of the GRACE risk score. Journal of Cardiology, 71(3), 251–258. doi: 10.1016/j.jjcc.2017.09.006.
de Oliveira, F. L., Gatto, M., Bassi, N., Luisetto, R., Ghirardello, A., Punzi, L., & Doria, A. (2015). Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med, 240(8), 1019–1028. doi: 10.1177/1535370215593826.
Aksan, G., Gedikli, Ö., Keskin, K., Nar, G., İnci, S., Yıldız, S. S., et al. (2016). Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis. J Investig Med, 64(3), 764–770. doi: 10.1136/jim-2015-000041.
Alturfan, A. A., Basar, I., Emekli-Alturfan, E., Ayan, F., Koldas, L., & Emekli, N. (2015). Galectin-3 and plasma cytokines in patients with acute myocardial infarction. Lab Med., 45(4), 336–341. doi: 10.1309/LM3JZKBDA7D4QFOC.
Milner, T. D., Viner, A. C., MacKinnon, A. C., Sethi, T., & Flapan, A. D. (2014). Temporal expression of galectin-3 following myocardial infarction. Acta Cardiol., 69(6), 595–602. doi: 10.2143/AC.69.6.1000001.
Weir, R. A., Petrie, C. J., Murphy, C. A., Clements, S., Steedman, T., Miller, A. M., et al. (2013). Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail., 6(3), 492–498. doi: 10.1161/CIRCHEARTFAILURE.112.000146.
Singsaas, E. G., Manhenke, C. A., Dickstein, K., & Orn, S. (2016). Circulating Galectin-3 levels are increased in patients with ischemic heart disease, but are not influenced by acute myocardial infarction. Cardiology, 134(4), 398–405. doi: 10.1159/000445103.
Szadkowska, I., Wlazel, R. N., Migala, M., Bajon-Laskowska, K., Szadkowski, K., Zielińska, M., et al. (2013). The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers, 18(8), 655–659. doi: 10.3109/1354750X.2013.840801.
Martínez-Martínez, E., Calvier, L., Rossignol, P., Rousseau, E., Fernández-Celis, A., Jurado-López, R., et al. (2016). Galectin-3 inhibition prevents adipose tissue remodelling in obesity. Int J Obes., 40(6), 1034–1038. doi: 10.1038/ijo.2016.19.
Schmidt, A. M. (2015). The growing problem of obesity: mechanisms, consequences, and therapeutic approaches. Arteriosclerosis, Thrombosis, and Vascular Biology, 35(6), 19–23. doi: 10.1161/ATVBAHA.115.305753.
Pugliese, G., Iacobini, C., Pesce, C. M., & Menini, S. (2015). Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology, 25(2), 136–150. doi: 10.1093/glycob/cwu111.
Nayor, M., Wang, N., Larson, M. G., Vasan, R. S., Levy, D., Ho, J. E. (2015) Circulating Galectin-3 is associated with cardiometabolic disease in the community. J Am Heart Asso., 5(1), pii: e002347. doi: 10.1161/JAHA.115.002347.
Ozturk, D., Celik, O., Satilmis, S., Aslan, S., Erturk, M., Cakmak, H. A., et al. (2015) Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis., 26(5), 396–401. doi: 10.1097/MCA.0000000000000252.
Papaspyridonos, M., McNeill, E., de Bono, J. P., Smith, A., Burnand, K. G., Channon, K. M., & Greaves, D. R. (2008) Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol., 28(3), 433–440. doi: 10.1161/ATVBAHA.107.159160.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
